Actively Recruiting
Vey Low-Energy Ketogenic Therapy in Adults With Type 1 Diabetes and Obesity on Intensive Insulin Therapy Using Advanded Hybrid Closed Loop System
Led by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Updated on 2025-09-29
14
Participants Needed
1
Research Sites
58 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Overweight and obesity are frequent in adults with type 1 diabetes (T1D), with prevalence exceeding 50% in recent studies. Excess weight in T1D is associated with higher cardiometabolic risk and therapeutic challenges, while effective and safe weight management strategies are still limited. This single-center, single-arm feasibility study will evaluate the efficacy and safety of a Very Low-Energy Ketogenic Therapy (VLEKT; 600-800 kcal/day) in adults with T1D and obesity treated with Advanced Hybrid Closed Loop (AHCL) insulin delivery systems. Participants will follow a structured 4-week program with commercial very-low-carbohydrate, high-protein meal replacements, under close medical supervision. The primary endpoint is change in body weight at 4 weeks. Secondary outcomes include body composition, muscle strength, glucose metrics, insulin requirements, biochemical parameters, and patient-reported outcomes. Safety will be assessed through hypoglycemia incidence, ketone monitoring, and occurrence of diabetic ketoacidosis (DKA). The study will enroll 14 participants. It is expected that VLEKT will achieve \~5% weight loss within one month while maintaining glycemic safety under AHCL technology.
CONDITIONS
Official Title
Vey Low-Energy Ketogenic Therapy in Adults With Type 1 Diabetes and Obesity on Intensive Insulin Therapy Using Advanded Hybrid Closed Loop System
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with type 1 diabetes or autoimmune diabetes for at least 12 months
- Body mass index (BMI) of 30 kg/m² or higher
- HbA1c less than 9%
- Knowledge and use of carbohydrate counting
- Using an Advanced Hybrid Closed Loop (AHCL) insulin system for at least 3 months and willing to keep using it during the study
- At least one diabetology follow-up visit in the past 12 months, including telemedicine
- Willingness to purchase meal replacements for the entire study duration
You will not qualify if you...
- Ketoacidosis, severe hypoglycemia with seizures or coma, or severe hyperglycemia requiring hospitalization in the past 6 months
- Febrile illness within the last 2 weeks
- Dietary restrictions or intolerances incompatible with study foods
- Celiac disease, gastroparesis, or food allergies
- Intense physical exercise over 2 hours on more than 3 days per week
- History or risk of eating disorders or other psychiatric disorders
- Recreational drug use or excessive alcohol consumption
- Chronic kidney disease with eGFR less than 60 ml/min
- Gallstones
- Liver failure
- Heart failure (NYHA class III-IV), unstable angina, cardiac arrhythmia, recent heart attack, or stroke within the past 12 months
- Respiratory failure
- Severe or active infections
- Planned elective surgery
- Rare metabolic diseases such as porphyria, CPT2 deficiency, mitochondrial fatty acid oxidation defect, or pyruvate carboxylase defect
- Current pregnancy or trying to conceive
- Breastfeeding
- Current glucocorticoid therapy except stable low-dose, inhaled, or replacement for adrenal insufficiency
- Other serious medical conditions that could interfere with participation or study completion
- Judged unable or unwilling to complete the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Policlinico Consorziale
Bari, Italy, Italy, 70124
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here